Effectiveness of Nonmydriatic Ultra-Widefield Retinal Imaging to Screen for Diabetic Eye Disease: A Randomized Controlled Trial (Clearsight)
Primary result · Actionable eye disease detectedResult — go to the resultAdjusted odds ratio 2.51 95% CI 1.49–4.36Authors' conclusion
Same-day, on-site screening by NM UWF imaging increased the detection of clinically important diabetic eye disease versus usual screening. Integration of NM UWF imaging into routine diabetes clinic visits improved screening adherence and has the potential to prevent vision loss.
Study context
- Population
- Adults with diabetes due for diabetic eye disease screening, St. Joseph's Health Care, London, Ontario, Canadarandomized
- Participants
- 740 adults
- Comparison
- Same-day on-site NM UWF screening vs usual screening
- On-site screeningn = 335
- Usual screeningn = 323reference
- Primary endpoint
- Detection of actionable eye disease (need for ophthalmology referral or increased ocular surveillance)
- Follow-up
- Within 1 year of enrollment
Methodological detailssingle-centre, parallel-group, Randomized between 7 March 2016 and 17 April 2019
- Single-centre
- Parallel-group
- Randomized between 7 March 2016 and 17 April 2019
Primary result
Actionable eye disease detected · within 1 year
Adjusted odds ratio
2.51
95% CI 1.49–4.36
Events by treatment group
On-site screeningvs Usual screening
aOR 2.51 (95% CI 1.49–4.36)
As reported in the abstract
- Number needed to screen to detect 1 additional patient with actionable eye disease (AED)
- 13 (95% CI 8-29)
Original publication
Effectiveness of Nonmydriatic Ultra-Widefield Retinal Imaging to Screen for Diabetic Eye Disease: A Randomized Controlled Trial (Clearsight). Diabetes Care. Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →